Dark

Check out our Level2View

ANCUSDT
Anoncoin / Tether USD
crypto

Inactive

Jun 4, 2024 8:42:00 AM EDT

0.0062USDT0.000%(0.0000)2140

Overview Historical DepthNews

Jan 28, 2022

08:01AM EST Updates on OLUMIANT(r) (baricitinib) Phase 3 lupus program and FDA review for PR Newswire

Jan 7, 2022

09:00AM EST Axial Spondyloarthritis to U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) PR Newswire

Dec 14, 2021

04:08PM EST U.S. FDA Approves Pfizer's XELJANZ(r) (tofacitinib) for the Treatment of Active Ankylosing Spondylitis Business Wire

Nov 18, 2021

01:30PM EST Pfizer's XELJANZ(r) (tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitis Business Wire

Nov 9, 2021

08:31AM EST OLUMIANT(r) Long-Term Safety Profile Established Up to 9.3 Years in Integrated PR Newswire

Oct 15, 2021

07:50AM EDT Pfizer's Abrocitinib Receives Positive CHMP Opinion for the Treatment of Adults with Moderate to Severe Atopic Dermatitis Business Wire

Oct 7, 2021

08:17AM EDT AbbVie's Upadacitinib (RINVOQ(r)) Met Primary and Most Ranked Secondary PR Newswire

08:15AM EDT AbbVie's RINVOQ(r) (upadacitinib) Met Primary and All Ranked Secondary PR Newswire

Oct 2, 2021

06:07PM EDT AbbVie to Showcase New Data at the United European Gastroenterology (UEG) Week PR Newswire

Sep 30, 2021

08:30AM EDT Dermatitis Across Patient Characteristics and Body Regions at EADV Virtual Congress PR Newswire

05:56AM EDT OLUMIANT(r) Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage PR Newswire

Sep 23, 2021

08:45AM EDT AbbVie Presents New Data Analyses for Growing Dermatology Portfolio at the 30th PR Newswire

Sep 16, 2021

08:01AM EDT (RINVOQ(r)) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis PR Newswire

Aug 24, 2021

08:01AM EDT the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis PR Newswire

Aug 20, 2021

04:31PM EDT XELJANZ(r) (tofacitinib citrate) Receives Marketing Authorization in the European Union for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis Business Wire

Jul 21, 2021

04:30PM EDT Pfizer Provides Update on U.S. FDA Review of Abrocitinib and XELJANZ(r) Filings Business Wire

Jul 16, 2021

10:01AM EDT Lilly and Incyte provide update on supplemental New Drug Application for PR Newswire

Jun 16, 2021

05:19PM EDT Data Published in New England Journal of Medicine Shows Pfizer's Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia Business Wire

Jun 1, 2021

07:31PM EDT OLUMIANT(r) Improved Pain, Physical Function and Morning Joint Stiffness in PR Newswire

May 4, 2021

06:43AM EDT permission for restricted emergency use as a COVID-19 therapy via donations and licensing agreements PR Newswire

Apr 23, 2021

10:01AM EDT Atopic Dermatitis and Other Patient-Reported Outcomes in Phase 3 Study Analyses PR Newswire

Apr 20, 2021

06:45AM EDT Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata PR Newswire

Apr 7, 2021

06:46AM EDT Pfizer Announces Extension of Review of New Drug Application of Abrocitinib for the Treatment of Moderate to Severe Atopic Dermatitis Business Wire

Apr 6, 2021

04:30PM EDT Application for baricitinib for the treatment of moderate to severe atopic dermatitis PR Newswire

Share